Study of Reactogenicity, Safety, Immunogenicity, and Pock Lesion Formation of a Cell-Cultured Smallpox Vaccine Compared to Dryvax®

Inclusion Criteria

• •Have never received smallpox vaccine or previously received an experimental smallpox vectored vaccine (for vaccinia-naive cohorts only)
• •Have been previously vaccinated within the last 10 years (vaccinia-experienced cohort only)
• •Must agree to have blood samples banked for future research testing
• •Have not participated in any clinical trial using investigational product within past month
• •No current or past history of exfoliative skin problems
• •Not have regular contact with children under 3 years of age until scab at site of vaccination has fallen off (around 21 days or 3 weeks after vaccination)
• •Do not have a positive test for HIV virus, hepatitis C virus, or hepatitis B surface antigen
• •Are not a health care worker caring for newborns, patients that are immunocompromised or have skin that is adversely altered
• •Will not engage in direct patient care until immunization scab falls off (around 21 days or 3 weeks after vaccination) if health care worker